C
Celltrion Pharm Inc
KOSDAQ:068760
Celltrion Pharm Inc
KOSDAQ:068760
Price:
53 000
KRW
0.76%
Market Closed
Market Cap:
2.2T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Celltrion Pharm Inc
53000
+400 (+0.76%)
| 52 Week Range |
52 500
129 100
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Celltrion Pharm Inc
Balance Sheet
Balance Sheet Decomposition
Celltrion Pharm Inc
Celltrion Pharm Inc
| Current Assets | 375.8B |
| Cash & Short-Term Investments | 43.1B |
| Receivables | 198B |
| Other Current Assets | 134.7B |
| Non-Current Assets | 276.8B |
| Long-Term Investments | 230.5m |
| PP&E | 223.9B |
| Intangibles | 39B |
| Other Non-Current Assets | 13.6B |
| Current Liabilities | 237.3B |
| Accounts Payable | 47.4B |
| Accrued Liabilities | 313m |
| Short-Term Debt | 150.5B |
| Other Current Liabilities | 39.1B |
| Non-Current Liabilities | 25.3B |
| Long-Term Debt | 15.6B |
| Other Non-Current Liabilities | 9.6B |
Balance Sheet
Celltrion Pharm Inc
Celltrion Pharm Inc
Currency: KRW
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
11 619
|
3 564
|
9 702
|
10 194
|
5 638
|
9 118
|
10 764
|
25 748
|
80 186
|
31 391
|
|
| Cash |
4
|
1
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
11 615
|
3 563
|
9 702
|
10 194
|
5 637
|
9 117
|
10 764
|
25 748
|
80 186
|
31 391
|
|
| Short-Term Investments |
0
|
0
|
715
|
315
|
315
|
0
|
2 568
|
4 000
|
7 975
|
12 702
|
|
| Total Receivables |
40 579
|
59 047
|
61 097
|
91 665
|
135 654
|
142 862
|
139 466
|
142 016
|
174 008
|
187 608
|
|
| Accounts Receivables |
34 793
|
40 087
|
43 434
|
80 823
|
123 639
|
132 736
|
138 794
|
140 509
|
172 491
|
185 945
|
|
| Other Receivables |
5 786
|
18 960
|
17 663
|
10 842
|
12 015
|
10 126
|
672
|
1 507
|
1 517
|
1 663
|
|
| Inventory |
82 315
|
75 926
|
73 742
|
78 872
|
65 243
|
42 017
|
33 102
|
55 014
|
63 887
|
69 177
|
|
| Other Current Assets |
6 381
|
7 887
|
4 094
|
3 796
|
4 257
|
5 964
|
2 956
|
4 176
|
5 084
|
11 040
|
|
| Total Current Assets |
140 895
|
146 424
|
149 350
|
184 843
|
211 107
|
199 961
|
188 855
|
230 954
|
331 140
|
311 918
|
|
| PP&E Net |
145 624
|
196 120
|
219 162
|
209 836
|
199 864
|
195 554
|
216 577
|
248 256
|
241 925
|
228 243
|
|
| PP&E Gross |
145 624
|
196 120
|
219 162
|
209 836
|
199 864
|
195 554
|
216 577
|
248 256
|
241 925
|
228 243
|
|
| Accumulated Depreciation |
5 149
|
6 901
|
13 439
|
24 855
|
36 519
|
48 244
|
59 378
|
70 562
|
84 897
|
101 290
|
|
| Intangible Assets |
13 333
|
23 811
|
49 822
|
62 538
|
6 994
|
2 908
|
3 450
|
5 139
|
6 517
|
8 411
|
|
| Goodwill |
32 912
|
32 912
|
32 912
|
32 912
|
32 912
|
32 912
|
32 912
|
32 912
|
32 912
|
32 912
|
|
| Note Receivable |
3 000
|
4 754
|
1 164
|
900
|
314
|
0
|
9 457
|
9 571
|
8 331
|
131
|
|
| Long-Term Investments |
1 306
|
306
|
933
|
1 333
|
1 333
|
1 582
|
2 223
|
933
|
933
|
230
|
|
| Other Long-Term Assets |
24 284
|
6 838
|
13 429
|
17 660
|
17 745
|
19 527
|
17 506
|
20 310
|
16 126
|
17 879
|
|
| Other Assets |
32 912
|
32 912
|
32 912
|
32 912
|
32 912
|
32 912
|
32 912
|
32 912
|
32 912
|
32 912
|
|
| Total Assets |
361 354
N/A
|
411 165
+14%
|
466 772
+14%
|
510 022
+9%
|
470 269
-8%
|
452 444
-4%
|
470 980
+4%
|
548 075
+16%
|
637 884
+16%
|
599 725
-6%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
936
|
864
|
2 238
|
12 765
|
13 169
|
12 376
|
6 810
|
21 613
|
72 593
|
38 073
|
|
| Accrued Liabilities |
2 594
|
2 789
|
1 628
|
394
|
954
|
1 635
|
1 466
|
1 870
|
2 367
|
394
|
|
| Short-Term Debt |
19 366
|
84 253
|
101 823
|
49 732
|
89 249
|
98 853
|
108 960
|
121 000
|
121 221
|
121 238
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
6 875
|
13 750
|
14 115
|
14 171
|
20 415
|
17 636
|
|
| Other Current Liabilities |
3 725
|
23 654
|
6 801
|
9 496
|
14 044
|
18 421
|
17 788
|
26 273
|
43 319
|
34 657
|
|
| Total Current Liabilities |
26 622
|
111 560
|
112 490
|
72 387
|
124 290
|
145 034
|
149 139
|
184 927
|
259 914
|
211 998
|
|
| Long-Term Debt |
165 570
|
84 401
|
114 089
|
89 000
|
48 125
|
34 375
|
38 811
|
57 851
|
39 398
|
21 823
|
|
| Other Liabilities |
749
|
778
|
3 959
|
3 987
|
4 230
|
3 000
|
3 000
|
4 736
|
6 603
|
9 117
|
|
| Total Liabilities |
192 941
N/A
|
196 739
+2%
|
230 537
+17%
|
165 375
-28%
|
176 646
+7%
|
182 409
+3%
|
190 949
+5%
|
247 514
+30%
|
305 916
+24%
|
242 938
-21%
|
|
| Equity | |||||||||||
| Common Stock |
140 294
|
9 445
|
10 429
|
307 298
|
309 705
|
310 878
|
263 549
|
264 858
|
266 559
|
268 324
|
|
| Retained Earnings |
17 375
|
23 244
|
29 506
|
32 109
|
20 910
|
45 123
|
11 168
|
31 566
|
65 787
|
91 199
|
|
| Additional Paid In Capital |
6 483
|
177 466
|
192 112
|
1 101
|
807
|
1 088
|
1 618
|
2 243
|
0
|
0
|
|
| Unrealized Security Profit/Loss |
319
|
329
|
284
|
285
|
269
|
470
|
974
|
277
|
96
|
96
|
|
| Treasury Stock |
14
|
14
|
52
|
101
|
203
|
1 233
|
1 233
|
2 337
|
7 572
|
12 149
|
|
| Other Equity |
3 955
|
3 955
|
3 955
|
3 955
|
3 955
|
3 955
|
3 955
|
3 955
|
7 291
|
9 508
|
|
| Total Equity |
168 412
N/A
|
214 426
+27%
|
236 234
+10%
|
344 648
+46%
|
293 624
-15%
|
270 035
-8%
|
280 031
+4%
|
300 561
+7%
|
331 969
+10%
|
356 787
+7%
|
|
| Total Liabilities & Equity |
361 354
N/A
|
411 165
+14%
|
466 772
+14%
|
510 022
+9%
|
470 269
-8%
|
452 444
-4%
|
470 980
+4%
|
548 075
+16%
|
637 884
+16%
|
599 725
-6%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
18
|
22
|
24
|
36
|
36
|
36
|
36
|
36
|
39
|
39
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
